INSM – Insmed Incorporated

Insmed Incorporated

INSM

$119.61

Name : Insmed Incorporated

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $26,238,982,144.00

EPSttm : -2.81

Insmed Incorporated

$119.61

0.10%

$0.115

INSM — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.24

Margin Of Safety %

Put/Call OI Ratio

0.44

EPS Next Q Diff

0.18

EPS Last/This Y

4.75

EPS This/Next Y

2.35

Price

119.51

Target Price

194.18

Analyst Recom

1.2

Performance Q

-9.67

Upside

-182.6%

Beta

0.81

Ticker: INSM

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	INSM	98.59	0.57	0.57	104351
2026-10-13	INSM	96.79	0.57	0.01	104366
2026-10-14	INSM	97.84	0.54	1.94	107569
2026-10-15	INSM	99.25	0.55	0.43	108935
2026-10-16	INSM	96.27	0.55	0.02	108864
2026-10-19	INSM	95.65	0.55	3.97	107666
2026-10-20	INSM	95.67	0.58	6.44	110158
2026-10-21	INSM	94.36	0.57	0.78	110945
2026-10-22	INSM	95.03	0.57	0.00	111397
2026-10-23	INSM	93.48	0.52	0.22	114858
2026-10-26	INSM	93.35	0.52	0.02	115471
2026-10-27	INSM	95	0.52	0.09	114523
2026-10-28	INSM	97.14	0.42	0.16	138327
2026-10-29	INSM	111.54	0.39	0.19	141179
2026-10-30	INSM	112.61	0.41	0.22	134734
2026-11-02	INSM	109.26	0.42	0.14	133599
2026-11-03	INSM	104.43	0.42	0.11	133451
2026-11-04	INSM	109.94	0.43	0.09	135347
2026-11-05	INSM	108.74	0.42	0.07	136572
2026-11-06	INSM	114.54	0.43	0.19	135566
2026-11-09	INSM	116.12	0.43	0.23	136414
2026-11-10	INSM	119.81	0.44	0.04	135644
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	INSM	98.59	78.6	1287.2	-1.57
2026-10-13	INSM	96.76	78.7	1288.1	-1.56
2026-10-14	INSM	97.82	78.4	1303.1	-1.59
2026-10-15	INSM	99.22	78.4	1310.6	-1.59
2026-10-16	INSM	96.30	78.3	1282.3	-1.59
2026-10-19	INSM	95.29	78.3	1292.2	-1.59
2026-10-20	INSM	95.29	78.3	1292.2	-1.59
2026-10-21	INSM	95.69	78.4	1299.7	-1.59
2026-10-22	INSM	95.00	78.4	1302.9	-1.59
2026-10-23	INSM	93.46	78.4	1289.1	-1.59
2026-10-26	INSM	93.36	78.4	1297.3	-1.59
2026-10-27	INSM	94.96	78.4	1306.6	-1.59
2026-10-28	INSM	97.17	78.4	1309.6	-1.59
2026-10-29	INSM	111.54	78.4	1375.4	-1.59
2026-10-30	INSM	112.60	78.4	1302.2	-1.59
2026-11-02	INSM	109.33	81.2	1011.7	-1.51
2026-11-03	INSM	104.46	79.5	989.4	-1.78
2026-11-04	INSM	109.96	78.1	1053.9	-1.74
2026-11-05	INSM	108.72	78.1	1020.6	-1.74
2026-11-06	INSM	114.40	78.6	1053.4	-1.74
2026-11-09	INSM	116.07	78.6	894.2	-1.74
2026-11-10	INSM	119.51	77.8	899.8	-1.67
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	INSM	-13.29	-0.55	6.41
2026-10-13	INSM	-13.29	-0.55	6.41
2026-10-14	INSM	-13.29	-0.55	6.41
2026-10-15	INSM	-13.29	-0.55	6.41
2026-10-16	INSM	-13.29	-0.55	6.41
2026-10-19	INSM	-13.04	-0.49	6.41
2026-10-20	INSM	-13.04	-0.49	6.41
2026-10-21	INSM	-13.04	-0.49	6.41
2026-10-22	INSM	-13.04	-0.49	6.41
2026-10-23	INSM	-13.04	-0.49	6.41
2026-10-26	INSM	-13.04	-0.20	6.41
2026-10-27	INSM	-13.04	-0.20	6.26
2026-10-28	INSM	-13.04	-0.20	6.26
2026-10-29	INSM	-13.04	-0.20	6.26
2026-10-30	INSM	-13.04	-0.20	6.26
2026-11-02	INSM	-12.99	-0.16	6.24
2026-11-03	INSM	-12.99	-0.16	6.24
2026-11-05	INSM	-12.99	-0.16	6.24
2026-11-06	INSM	-12.99	-0.16	6.24
2026-11-09	INSM	-12.74	5.57	6.24
2026-11-10	INSM	-12.74	5.57	6.24
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.46

Avg. EPS Est. Current Quarter

-0.34

Avg. EPS Est. Next Quarter

-0.28

Insider Transactions

-12.74

Institutional Transactions

5.57

Beta

0.81

Average Sales Estimate Current Quarter

604

Average Sales Estimate Next Quarter

625

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

43.8

Max Drawdown 5-Year %

-56.5

Target Price

194.18

P/E

Forward P/E

171.89

PEG

P/S

17.25

P/B

36.09

P/Free Cash Flow

EPS

-2.82

Average EPS Est. Cur. Y

-1.67

EPS Next Y. (Est.)

0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-39.85

Relative Volume

1.2

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-90

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.12

EBIT Estimation

899.8

◆ INSM Healthcare

$119.49

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

14/20

Pullback

6/25

Volume

1/15

Valuation

15/20

TP/AR

2/10

Options

7/10

RSI

65.5

Range 1M

95.5%

Sup Dist

4.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

10/25

Growth

25/30

Estimates

2/20

Inst/Vol

7/15

Options

9/10

EPS Yr

74.4%

EPS NY

142.3%

52W%

23%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -39.4% upside

Quality

6/30

Valuation

0/30

Growth

17/25

Stability

7/10

LT Trend

3/5

Upside

-39.4%

Quality

INSM — P/E HistoricalBiotechnology

Insmed Incorporated

Sector: Healthcare

Industry: Biotechnology

Employees: 1664

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

INSM

Latest News

—

Caricamento notizie per INSM…

stock quote shares INSM – Insmed Incorporated Stock Price stock today

news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch INSM – Insmed Incorporated yahoo finance google finance

stock history INSM – Insmed Incorporated invest stock market

stock prices INSM premarket after hours

ticker INSM fair value insiders trading

INSM – Insmed Incorporated

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: INSM

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y